SPINRAZA® has fundamentally changed the course of disease in Adult patients compared with natural history.2 Directly administered into the CNS, the targeted mechanism of action provides sustained efficacy at the source of SMA protein production with a well-established safety profile.2
20 years*Type III SMA, treated with
SPINRAZA® more than
5 years as of 2018.
*Age at time of photoshoot
Interview with Prof. Christoph Kleinschnitz, Director of the Clinic for Neurology, Essen University Hospital discussing the importance of treating Adults with SMA.
1. Biogen JP Morgan 2020 Presentation. Available at: http://investors.biogen.com/static-files/ad405cb6-f526-4d2a-9d4a-2318b46dea43
2. Hagenacker T., et al, Nusinersen adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurology 2020; 19:317-25.
3. SPINRAZA® Summary of Product Characteristics.